Predictions of random forests (RF), gradient boosting machines (GBM), and neural networks (NN) trained on 17 covariates selected after recursive feature selection. by Dennis Ochola (11626912)

(a) Histogram of relative phase at all steps for all participants. by Shinnosuke Hase (20917896)

Graphical representation of a stepped-wedge design with 6 sequences. by Mirjam Moerbeek (8603520)

Decrease of cellular cAMP levels in response to a concentration range of melatonin treatments. by Cathryn S. D. Maienza (20629929)

The conduction velocity for a cell distance of 4 <i>μ</i>m is nearly constant as the magnitude of the extracellular potential decreases. by Karoline Horgmo Jæger (6785450)

Seven out of the 11 human cytidine deaminases are more highly expressed in tumor versus normal tissue and their higher expression is correlated with a decrease in survival. by Mason A. McCool (11889842)

Schematic illustration of the possible steps for the rupture of a ‘single GUV’. by Md. Tariqul Islam Bhuiyan (18794375)

Algorithm operation steps. by Junyan Wang (4738518)

Network response to 500 ms step stimuli of a single odorant for the network as shown in Fig 2. by Mario Pannunzi (553941)

Parthenolide Derivatives as PKM2 Activators Showing Potential in Colorectal Cancer by Xingchen Liu (524190)

“…As a vital kinase in the glycolysis system, PKM2 is extensively expressed in colorectal cancer (CRC) to support the energy and biosynthetic needs. In this study, we designed a series of parthenolide (PTL) derivatives through a stepwise structure optimization, and an excellent derivate <b>29e</b> showed good activity on PKM2 (AC₅₀ = 86.29 nM) and displayed significant antiproliferative activity against HT29 (IC₅₀ = 0.66 μM) and SW480 (IC₅₀ = 0.22 μM) cells. …”

Parthenolide Derivatives as PKM2 Activators Showing Potential in Colorectal Cancer by Xingchen Liu (524190)

“…As a vital kinase in the glycolysis system, PKM2 is extensively expressed in colorectal cancer (CRC) to support the energy and biosynthetic needs. In this study, we designed a series of parthenolide (PTL) derivatives through a stepwise structure optimization, and an excellent derivate <b>29e</b> showed good activity on PKM2 (AC₅₀ = 86.29 nM) and displayed significant antiproliferative activity against HT29 (IC₅₀ = 0.66 μM) and SW480 (IC₅₀ = 0.22 μM) cells. …”

Parthenolide Derivatives as PKM2 Activators Showing Potential in Colorectal Cancer by Xingchen Liu (524190)

“…As a vital kinase in the glycolysis system, PKM2 is extensively expressed in colorectal cancer (CRC) to support the energy and biosynthetic needs. In this study, we designed a series of parthenolide (PTL) derivatives through a stepwise structure optimization, and an excellent derivate <b>29e</b> showed good activity on PKM2 (AC₅₀ = 86.29 nM) and displayed significant antiproliferative activity against HT29 (IC₅₀ = 0.66 μM) and SW480 (IC₅₀ = 0.22 μM) cells. …”

Parthenolide Derivatives as PKM2 Activators Showing Potential in Colorectal Cancer by Xingchen Liu (524190)

“…As a vital kinase in the glycolysis system, PKM2 is extensively expressed in colorectal cancer (CRC) to support the energy and biosynthetic needs. In this study, we designed a series of parthenolide (PTL) derivatives through a stepwise structure optimization, and an excellent derivate <b>29e</b> showed good activity on PKM2 (AC₅₀ = 86.29 nM) and displayed significant antiproliferative activity against HT29 (IC₅₀ = 0.66 μM) and SW480 (IC₅₀ = 0.22 μM) cells. …”

Parthenolide Derivatives as PKM2 Activators Showing Potential in Colorectal Cancer by Xingchen Liu (524190)

“…As a vital kinase in the glycolysis system, PKM2 is extensively expressed in colorectal cancer (CRC) to support the energy and biosynthetic needs. In this study, we designed a series of parthenolide (PTL) derivatives through a stepwise structure optimization, and an excellent derivate <b>29e</b> showed good activity on PKM2 (AC₅₀ = 86.29 nM) and displayed significant antiproliferative activity against HT29 (IC₅₀ = 0.66 μM) and SW480 (IC₅₀ = 0.22 μM) cells. …”

Temporal profiles of the key BO-NN features. by Julia Berezutskaya (9080269)

“…Right plot show the gradual decrease in the TM tuning for the features highlighted in <b>c</b> as well as the gradual increase in the temporal response profile (i.e. optimal shifts for the prediction of the key BO-NN features using Praat features shown in <b>a</b>). …”

Flowchart of the steps involved in the high-throughput exoproteome screening assay (HESA). by Marion Schoof (11999106)

The inhibitory activity of the most active compounds against Glo-I enzyme with less than 50 µM. Their supportive corresponding docking values on two different protocols are display... by MohammedBashar Al-Qazzan (22439236)

Trace-weighted images at b = 50 s/mm². by Tobit Führes (12647099)

Repeated LSPC treatment prolongs survival of and decreases PrP^Res accumulation in a subset of prion-infected mice. by Heather Bender (363996)

A heatmap of the -log10(adj.pvalues) from AME enrichment testing within increasing and decreasing sites. by Spencer L. Nystrom (8730641)